Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMDNRU1)

Drug Name

RNS-60 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Asthma	CA23	Phase 2	[1]
Multiple sclerosis	8A40	Phase 2	[2]
Amyotrophic lateral sclerosis	8B60.0	Phase 1	[2]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Heat shock protein 90 (HSP90)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LAM-003	DMQHWMJ	Acute myeloid leukaemia	2A60	Phase 1	[4]
RTA 901	DMA6JME	Diabetic neuropathy	8C0Z	Phase 1	[5]
ADX-1612	DM86WI0	Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 1	[6]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	ClinicalTrials.gov (NCT01714089) Proof of Concept Study Evaluating RNS60 in the Treatment of Relapsing Remitting Multiple Sclerosis. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Clinical pipeline report, company report or official report of Revalesio.
4	LAM-003, a new drug for treatment of tyrosine kinase inhibitor-resistant FLT3-ITD-positive AML. Blood Adv. 2019 Nov 26;3(22):3661-3673.
5	Clinical pipeline report, company report or official report of Reata Pharmaceuticals.
6	Role of Ganetespib, an HSP90 Inhibitor, in Cancer Therapy: From Molecular Mechanisms to Clinical Practice. Int J Mol Sci. 2023 Mar 6;24(5):5014.